The following constitutes Amendment No. 3 to the Schedule 13D filed by the undersigned (“Amendment No. 3”). This Amendment No. 3 amends the Schedule 13D as specifically set forth herein.
Item 3. | Source and Amount of Funds or Other Consideration. |
Item 3 is hereby amended and restated to read as follows:
The aggregate purchase price of the 118,172 Shares owned directly by ALS Fund is approximately $2,122,177, including brokerage commissions. The Shares owned by ALS Fund were acquired with partnership funds.
The aggregate purchase price of the 1,069,187 Shares owned directly by ALS Fund Offshore is approximately $19,432,216, including brokerage commissions. The Shares owned by ALS Fund Offshore were acquired using its working capital.
Each of the Accipiter Entities effects purchases of securities primarily through margin accounts maintained for it with prime brokers, which may extend margin credit to it as and when required to open or carry positions in the margin accounts, subject to applicable federal margin regulations, stock exchange rules and the prime brokers’ credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debt balances in the accounts.
Item 5. | Interest in Securities of the Issuer. |
Item 5 is hereby amended and restated to read as follows:
(a) The aggregate percentage of Shares reported owned by each person named herein is based upon 24,996,058 Shares outstanding, which is the total number of Shares outstanding as of March 3, 2014 as reported in the Issuer’s Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on March 21, 2014.
As of the close of business on April 23, 2014, ALS Fund beneficially owned 118,172 Shares, constituting less than 1% of the Shares outstanding. Each of Candens Capital, as the general partner of ALS Fund, and Accipiter Management, as the investment manager of ALS Fund, may be deemed to beneficially own the 118,172 Shares owned by ALS Fund, constituting less than 1% of the Shares outstanding.
As of the close of business on April 23, 2014, ALS Fund Offshore beneficially owned 1,069,187 Shares, constituting approximately 4.3% of the Shares outstanding. As the investment manager of ALS Fund Offshore, Accipiter Management may be deemed to beneficially own the 1,069,187 Shares owned by ALS Fund Offshore, constituting approximately 4.3% of the Shares outstanding.
Accipiter Management, as the investment manager of the Accipiter Entities, and Mr. Hoffman, as the managing member of each of Accipiter Management and Candens Capital, may be deemed to beneficially own 1,187,359 Shares collectively owned by the Accipiter Entities, constituting approximately 4.8% of the Shares outstanding. Mr. Hoffman has sole voting and dispositive power with respect to the 1,187,359 Shares owned by the Accipiter Entities by virtue of his authority to vote and dispose of such shares.
The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any Shares he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that he or it does not directly own.
(b) By virtue of his positions with Accipiter Management and Candens Capital, Mr. Hoffman has the sole power to vote and dispose of the Shares reported in this Schedule 13D.
(c) Schedule A annexed hereto lists all transactions by the Reporting Persons in securities of the Issuer during the past sixty days. All of such transactions were effected in the open market.
(d) No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.
(e) As of April 23, 2014, the Reporting Persons ceased to be the beneficial owners of more than 5% of the outstanding Shares of the Issuer.
SIGNATURES
After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: April 28, 2014 | ACCIPITER LIFE SCIENCES FUND, LP |
| |
| By: | Candens Capital, LLC its general partner |
| |
| By: | /s/ Gabe Hoffman |
| | Gabe Hoffman, Managing Member |
| ACCIPITER LIFE SCIENCES FUND (OFFSHORE), LTD. |
| |
| By: | Accipiter Capital Management, LLC its investment manager |
| |
| By: | /s/ Gabe Hoffman |
| | Gabe Hoffman, Managing Member |
| ACCIPITER CAPITAL MANAGEMENT, LLC |
| |
| By: | /s/ Gabe Hoffman |
| | Gabe Hoffman, Managing Member |
| CANDENS CAPITAL, LLC |
| |
| By: | /s/ Gabe Hoffman |
| | Gabe Hoffman, Managing Member |
| /s/ Gabe Hoffman |
| GABE HOFFMAN |
SCHEDULE A
Transactions in the Shares by the Reporting Persons during the past sixty days
Shares of Common Stock Purchased/(Sold) | Price Per Share($) | Date of Transaction |
ACCIPITER LIFE SCIENCES FUND, LP
(45,634) | | 16.2996 | 04/23/2014 |
ACCIPITER LIFE SCIENCES FUND (OFFSHORE), LTD.
(114,366) | | 16.2996 | 04/23/2014 |